Home > Resources > Company Profiles > Alcon, Inc.

Alcon, Inc. (ACL)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Enter the text you see in the image *

Letters are not case-sensitive, disregard spaces.

Try a New One

This helps us prevent automated registrations and spamming.

Email Confirmation

Cary R. Rayment , CEO/Chairman of the Board/President/Director

www.alconinc.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

A global medical specialty company, that develops, manufactures and markets pharmaceuticals, surgical equipment & devices and consumer eye care products to treat primarily diseases & disorders of the eye.

Portfolio Articles

Eye on a Huge Deal
Novartis in a $39 billion transaction with Nestlé.
Apr 07 2008
Pharma's Fees
How the big drugmakers tend to your doctor.
Nov 19 2007

See more news on this company

News Feeds

ADRs in Focus: European pharma shares rise AP
Jul 08 2008
Novartis closer to $38B Alcon takeover AP
Jul 08 2008
Out of the Gate: Novartis rises AP
Jul 08 2008
Alcon, Advanced Medical Optics in licensing deal AP
Jun 24 2008
Alcon spent $240,000 lobbying in 1st quarter AP
Jun 20 2008
FDA panel wants stricter contact lens labeling AP
Jun 10 2008

Portfolio Blogs

Eyeball Datapoint of the Day
Apr 07 2008

Press Releases

Novartis Completes Purchase of Minority Interest in Alcon Jul-08-2008, 01:45AM EDT
Zacks Bull and Bear of the Day Highlights: AK Steel, CSX Corporation, Alcon, Hudson City Bancorp and LM Ericsson Jun-30-2008, 06:00AM EDT
Advanced Medical Optics Enters into Cross-Licensing Patent Agreement with Alcon Jun-24-2008, 06:00AM EDT
Alcon Enters Into Patent Cross-Licensing Agreement With AMO Jun-24-2008, 06:00AM EDT
Alcon Announces Second Quarter 2008 Financial Release and Conference Call Dates Jun-17-2008, 05:05PM EDT

News From Around the Web

News

Novartis Finds Defense in Alcon (The Street)

Jul 08 2008
Novartis Closes First Step in Alcon Deal (The Street)

Jul 08 2008
Novartis completes first stage in $38 billion takeover of eye-care company Alcon (Grand Forks Herald)

Jul 08 2008
Novartis Completes First Part In Buy Of Alcon Inc From Nestle (Wall Street Journal)

Jul 08 2008
Novartis Wraps First Step in Alcon Deal (Wall Street Journal)

Jul 08 2008
Novartis completes acquisition of minority interest in Alcon - Quick Facts (RTTNews)

Jul 08 2008
Update: Novartis closes on 25% of Alcon from Nestle (MarketWatch)

Jul 08 2008
Novartis completes first step of Alcon buy (Reuters)

Jul 08 2008
These Stocks Beat India's Stocks (Motley Fool)

Jul 07 2008
Refractive errors after PK improve after surface ablation and MMC (Modern Medicine)

Jul 02 2008

Employees

Number of Employees: 14,500

Revenue per Employee: $396,652

Top Executives

Ed McGough, Senior VP, Subsidiary

Jacqualyn A. Fouse, CFO/Senior VP, Divisional/Other Corporate Officer

Stefan Basler, Other Corporate Officer

Joanne Beck, General Manager

Martin Schneider, Other Corporate Officer

Richard J. Croarkin, CFO/Senior VP, Divisional

Dr. Gerald D. Cagle, Senior VP, Subsidiary/Other Executive Officer

Elaine E. Whitbeck, General Counsel/Secretary/Senior VP, Subsidiary/Other Executive Officer

Kevin J. Buehler, Senior VP, Subsidiary/Other Executive Officer

Board of Directors

Lodewijk J.R. de Vink, Director

Francisco Castaner, Director/Vice Chairman

Gerhard N. Mayr, Director

Thomas G. Plaskett, Director

Dr. Werner J. Bauer, Director

Joseph M. Weller, Director

Paul Polman, Director

Financials

Quarterly

Annual

Income Statement	04/2008	02/2008	10/2007	08/2007
Sales	346.3 Mil.	331.1 Mil.	174.8 Mil.	363.6 Mil.
Gross Operating Profit	1.19 Bil.	1.14 Bil.	1.16 Bil.	1.11 Bil.
Operating Income before D & A (EBITDA)	561 Mil.	537 Mil.	626.2 Mil.	536.5 Mil.
Total Income Before Interest Expenses (EBIT)	520.9 Mil.	517.3 Mil.	482.6 Mil.	563.8 Mil.
Total Net Income	429.4 Mil.	376.5 Mil.	415.3 Mil.	448.4 Mil.
Basic EPS, Total	1.44	1.27	1.39	1.5
Diluted EPS, Total	1.43	1.27	1.38	1.48

BALANCE STATEMENT	04/2008	02/2008	10/2007	08/2007
Cash and Equivalents	2.5 Bil.	2.13 Bil.	826.9 Mil.	576.3 Mil.
Total Assets	5.38 Bil.	4.82 Bil.	3.5 Bil.	3.19 Bil.
Total Liabilities	2.9 Bil.	2.86 Bil.	1.9 Bil.	1.81 Bil.
Total Capitalization	3.99 Bil.	3.43 Bil.	3.1 Bil.	2.7 Bil.

Cash Flow	04/2008	02/2008	10/2007	08/2007
Net Cash From Continuing Operations	398.1 Mil.	1.47 Bil.	814.7 Mil.	346.7 Mil.
Net Cash From Investing Activities	-68.6 Mil.	-227.1 Mil.	-63.3 Mil.	25 Mil.
Net Cash From Financing Activities	31.3 Mil.	-606.6 Mil.	-1.42 Bil.	-1.29 Bil.
Net Change in Cash & Cash Equivalents	365.4 Mil.	645.1 Mil.	-662.3 Mil.	-912.9 Mil.

Income Statement	2008	2007	2006	2005
Sales	1.24 Bil.	1.06 Bil.	950.9 Mil.	956 Mil.
Gross Operating Profit	4.36 Bil.	3.84 Bil.	3.42 Bil.	2.96 Bil.
Operating Income before D & A (EBITDA)	2.1 Bil.	1.93 Bil.	1.4 Bil.	1.33 Bil.
Total Income Before Interest Expenses (EBIT)	2 Bil.	1.66 Bil.	1.24 Bil.	1.15 Bil.
Total Net Income	1.59 Bil.	1.35 Bil.	931 Mil.	871.8 Mil.
Basic EPS, Total	5.32	4.43	3.04	2.85
Diluted EPS, Total	5.25	4.37	2.98	2.8

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	2.13 Bil.	1.49 Bil.	1.46 Bil.	1.09 Bil.
Total Assets	4.82 Bil.	3.46 Bil.	3.27 Bil.	2.64 Bil.
Total Liabilities	2.86 Bil.	2 Bil.	2.28 Bil.	1.88 Bil.
Total Capitalization	3.43 Bil.	2.96 Bil.	2.61 Bil.	2.26 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	1.47 Bil.	1.41 Bil.	1.24 Bil.	1.05 Bil.
Net Cash From Investing Activities	-227.1 Mil.	-166.1 Mil.	-382.3 Mil.	-255.5 Mil.
Net Cash From Financing Activities	-606.6 Mil.	-1.22 Bil.	-433 Mil.	-822.7 Mil.
Net Change in Cash & Cash Equivalents	645.1 Mil.	32 Mil.	363.8 Mil.	7.4 Mil.

Alcon, Inc. (ACL)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request